Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics Inc (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company advancing novel therapies for dermatological conditions, oncology targets, and neurodegenerative disorders. This news hub provides investors and researchers with timely updates on clinical trial progress, regulatory milestones, and strategic partnerships central to evaluating Hoth’s therapeutic pipeline.
Discover authoritative coverage of Hoth’s innovative platforms including the BioLexa antimicrobial system and HT-ALZ for Alzheimer’s research. Our curated news collection features press releases on FDA designations, preclinical data disclosures, and licensing agreements with academic institutions like George Washington University and North Carolina State University.
Key updates include developments across three core areas: dermatology (eczema/chronic wound treatments), oncology (HT-KIT for mast cell cancers), and neurology (neuroinflammation targeting). Each news item is verified for accuracy to support informed analysis of Hoth’s research trajectory and market position.
Bookmark this page for consolidated access to Hoth Therapeutics’ latest announcements, including earnings reports, intellectual property filings, and collaborative research initiatives. Regularly updated to serve as your primary resource for tracking this innovative biopharma’s progress in addressing unmet medical needs.
Hoth Therapeutics (NASDAQ: HOTH) has announced positive data from a first-of-its-kind human patient treatment using HT-001 for epidermal growth factor receptor inhibitor (EGFRI) associated papulopustular eruptions (PPEs). The patient, a 59-year-old female with metastatic breast cancer, experienced significant symptom improvement after just one week of treatment, allowing her to discontinue HT-001 after only seven days. This rapid success highlights HT-001's potential as an effective therapy for EGFRI-associated skin toxicities, which affect up to 90% of cancer patients undergoing EGFRI therapy. A Phase 2a clinical trial is currently underway to further evaluate HT-001's efficacy and safety, with multiple prestigious cancer centers participating in the study.
Hoth Therapeutics (NASDAQ: HOTH) has entered a Master Services Agreement with Aronnax Inc. for its HT-KIT cancer therapeutic. Aronnax will oversee ITR Laboratories in conducting intravenous injection studies to determine the Maximum-Tolerated Dose (MTD) and perform a Dose Range-Finding Phase for HT-KIT.
HT-KIT, an antisense oligonucleotide targeting the proto-oncogene cKIT, has shown promising results in killing human mast cells and reducing KIT expression in GIST and AML cells. It has received Orphan Drug Designation from the FDA for treating mast cell-derived cancers and anaphylaxis.
This study aims to provide Hoth with key metrics for formulating its proposed clinical trial, advancing HT-KIT towards an IND-enabling study.
Hoth Therapeutics (NASDAQ: HOTH) has partnered with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer's disease treatment. This collaboration follows promising pre-clinical results that demonstrated HT-ALZ's ability to improve cognitive functions and quality of life in subjects with Alzheimer's.
The treatment showed potential to reduce brain inflammation, leading to improved cognitive outcomes. Pre-clinical research indicated HT-ALZ's capacity to enhance memory tasks related to the hippocampus and sensorimotor gating. The prototype development will support a future Investigational New Drug (IND) Application to initiate clinical trials, marking a significant step in Hoth's innovative approach to Alzheimer's treatment.
Hoth Therapeutics (NASDAQ: HOTH) has expanded its First-in-Human Phase 2a clinical trial for HT-001, a treatment for skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi) in cancer patients. The company received approval from three prestigious medical centers: GW University Hospital, UC Irvine, and Northwell Health.
The trial aims to investigate the efficacy, safety, and tolerability of topical HT-001. CEO Robb Knie expressed optimism that the trial will demonstrate successful delivery of their lead therapeutic candidate and provide hope for cancer patients suffering from EGFRi-related skin toxicities. More information about this dose-ranging study is available on clinicaltrials.gov.
Hoth Therapeutics (NASDAQ: HOTH) has entered a joint development agreement with Wise Systems International SRL, using Nvidia's BioNeMo generative AI platform. This collaboration aims to accelerate the drug discovery process by utilizing AI for target identification and lead optimization. The partnership is expected to enhance Hoth's therapeutic pipeline and increase the value of its assets. Key executives from both companies expressed optimism about leveraging AI to bring innovative treatments to patients.
Hoth Therapeutics, Inc. (HOTH) will have its CEO attend the EF Hutton Annual Global Conference in New York, NY. The conference provides networking opportunities and a platform to showcase the company's biopharmaceutical endeavors.
FAQ
What is the current stock price of Hoth Therapeutics (HOTH)?
What is the market cap of Hoth Therapeutics (HOTH)?
